All In Biotech

Investigational drug · Phase 2

AP203

Not approved by FDA. In 1 industry-sponsored Phase 2 or 3 trial that is active or finished in the last two years, most often for Locally Advanced or Metastatic Solid Tumors, Non Small Cell Lung Cancer (NSCLC), Head and Neck Squamous Cell Carcinoma (HNSCC).

Phase 2

Last checked: Nov 19, 2026Latest source record: Mar 26, 2025 (newest trial update)Source: ClinicalTrials.govMethods & limitations

Highest phase

Phase 2

Industry-sponsored trials

Phase 2 and 3 trials

1

1 still active

All registered trials

1

Any phase or sponsor naming "AP203"

First trial start

2023

Jul 24, 2023

Sponsors

Lead sponsors of its Phase 2 and 3 trials.

All registered trials by phase

Every ClinicalTrials.gov drug study naming "AP203", any sponsor or status.

Conditions studied

As listed on its trial records.

  • Locally Advanced or Metastatic Solid Tumors
  • Non Small Cell Lung Cancer (NSCLC)
  • Head and Neck Squamous Cell Carcinoma (HNSCC)
  • Esophageal Squamous Cell Carcinoma (ESCC)

Approved drugs for the same conditions: Non-small cell lung cancer · Small cell lung cancer · Stomach and esophageal cancer · Head and neck cancer · Oncology · Gastroenterology and liver

Largest trials

Live from ClinicalTrials.gov: studies naming "AP203" as an intervention, largest first.

All trials

Newest research

PubMed records naming it or its code names, newest first.

All 5 on PubMed

Also in development for Locally Advanced or Metastatic Solid Tumors

  • CVL237Phase 22 trials

    Convalife (Shanghai) Co., Ltd. · Advanced Solid Tumors, Locally Advanced or Metastatic Solid Tumors, PTEN Loss or Low Expression

  • MediLink Therapeutics (Suzhou) Co., Ltd. · NSCLC, Breast Cancer, HNSCC

  • ASP388BPhase 21 trial

    Astellas · Locally Advanced or Metastatic Solid Tumors

  • BC3195Phase 21 trial

    Biocity Biopharmaceutics Co., Ltd. · Locally Advanced or Metastatic Solid Tumors

  • DA-4505Phase 21 trial

    Dong-A ST Co., Ltd. · Locally Advanced or Metastatic Solid Tumors

  • PTT-936Phase 21 trial

    Pyrotech Therapeutics, Inc. · Locally Advanced or Metastatic Solid Tumors

  • XZP-5955Phase 21 trial

    Xuanzhu Biopharmaceutical Co., Ltd. · Locally Advanced or Metastatic Solid Tumors, Locally Advanced or Metastatic Non-small Cell Lung Cancer

Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.